Newsroom

Sight Sciences Announces Positive Clinical Results from Randomized, Controlled Trial of TearCare for the Treatment of Dry Eye Disease

Data Presented at the ASCRS Virtual Meeting Shows the Novel Eyelid Procedure Met All Dry Eye Signs and Symptoms Endpoints

read more +
Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the launch of its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS) procedures.

read more +
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D.

read more +
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today...

read more +
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new...

read more +
Sight Sciences Appoints Erica Rogers to its Board of Directors

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the appointment of Erica Rogers...

read more +
International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚...

read more +
First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from...

read more +